HutchMed Shifts Focus to Late-Stage Pipeline for Regulatory Approvals
Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) has announced a strategic shift to focus...
HutchMed
HutchMed Announces Initial Results from FRUTIGA Phase III Study
China-based Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) has announced the initial results from...
CIIE: MET HER2 Precision Diagnosis Alliance Formed to Advance Lung Cancer Treatment
The 5th China International Import Expo (CIIE) witnessed the establishment of the MET HER2 precision...
HutchMed Initiates Phase II/III Study of Sovleplenib for Warm AIHA
China-based Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) has announced the initiation of a...
China-U.S. Listing Agreement Clears Path for Chinese Firms to Stay Listed in the U.S.
China and the United States are nearing an agreement that would allow Chinese firms to...
Inmagene and HutchMed Dose First Subject in IMG-004 Phase I Study
China-based Inmagene Biopharmaceuticals and Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) announced that the...
HutchMed’s FRESCO-2 Study for Elunate in Colorectal Cancer Meets Primary Endpoint
China-based Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) announced that the pivotal global Phase...